KR20010029519A
(ko)
*
|
1996-09-19 |
2001-04-06 |
이곤 이 버그 |
요실금 치료 방법
|
US20100137358A1
(en)
*
|
1996-11-05 |
2010-06-03 |
Dr. Reddy's Laboratories Ltd. |
Solifenacin compositions
|
IL141235A
(en)
*
|
2000-02-09 |
2012-04-30 |
Novartis Int Pharm Ltd |
Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
|
US7858119B1
(en)
*
|
2000-05-09 |
2010-12-28 |
Amina Odidi |
Extended release pharmaceuticals
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
DE10149674A1
(de)
*
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
|
US7163696B2
(en)
*
|
2001-10-11 |
2007-01-16 |
Pfizer Inc. |
Pharmaceutical formulations
|
US8329217B2
(en)
|
2001-11-06 |
2012-12-11 |
Osmotica Kereskedelmi Es Szolgaltato Kft |
Dual controlled release dosage form
|
US20030185882A1
(en)
*
|
2001-11-06 |
2003-10-02 |
Vergez Juan A. |
Pharmaceutical compositions containing oxybutynin
|
GB0129962D0
(en)
*
|
2001-12-14 |
2002-02-06 |
Pfizer Ltd |
Method of treatment
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
CA2451267A1
(en)
*
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
CA2679030A1
(en)
|
2002-12-13 |
2004-07-01 |
Warner-Lambert Company Llc |
Alpha-2-delta ligand to treat lower urinary track symptoms
|
US20040235857A1
(en)
*
|
2003-02-11 |
2004-11-25 |
Pfizer Inc |
Crystalline therapeutic agent
|
PA8597401A1
(es)
*
|
2003-03-14 |
2005-05-24 |
Pfizer |
Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
|
US20040186046A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
ES2326119T3
(es)
|
2003-04-29 |
2009-10-01 |
Pfizer Inc. |
5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
|
US7268147B2
(en)
*
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
CA2529984C
(en)
|
2003-06-26 |
2012-09-25 |
Isa Odidi |
Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
|
US20050043300A1
(en)
*
|
2003-08-14 |
2005-02-24 |
Pfizer Inc. |
Piperazine derivatives
|
CN100482659C
(zh)
*
|
2003-09-03 |
2009-04-29 |
辉瑞大药厂 |
具有5-ht4受体激动活性的苯并咪唑酮化合物
|
EP1663398B1
(de)
|
2003-09-12 |
2009-11-25 |
Pfizer Limited |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
EP1682545B1
(de)
*
|
2003-10-03 |
2007-12-12 |
Pfizer Limited |
Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
|
US7572799B2
(en)
*
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
GB0327323D0
(en)
*
|
2003-11-24 |
2003-12-31 |
Pfizer Ltd |
Novel pharmaceuticals
|
GB0402491D0
(en)
*
|
2004-02-04 |
2004-03-10 |
Pfizer Ltd |
Medicaments
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
US7629358B2
(en)
*
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US7687533B2
(en)
*
|
2004-03-18 |
2010-03-30 |
Pfizer Inc. |
N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
|
US20050215542A1
(en)
*
|
2004-03-23 |
2005-09-29 |
Pfizer Inc |
Compounds for the treatment of diseases
|
PL1730103T3
(pl)
*
|
2004-03-23 |
2010-10-29 |
Pfizer |
Pochodne formamidu użyteczne jako adrenoreceptor
|
US7538141B2
(en)
*
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
US7569572B2
(en)
*
|
2004-04-07 |
2009-08-04 |
Pfizer Inc |
Pyrazolo[4,3-D]pyrimidines
|
US7737163B2
(en)
*
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
GEP20094638B
(en)
*
|
2004-06-15 |
2009-03-10 |
Pfizer |
Benzimidazolone carboxylic acid derivatives
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
PT1778686E
(pt)
|
2004-08-12 |
2008-12-26 |
Pfizer |
Derivados de triazolopiridinilsufanilo como inibidores da p38 map-cinase
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
CA2577937C
(en)
*
|
2004-08-26 |
2010-12-21 |
Pfizer Inc. |
Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
|
UA87153C2
(ru)
|
2004-08-26 |
2009-06-25 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
|
CA2586179C
(en)
*
|
2004-11-02 |
2011-02-08 |
Pfizer Inc. |
Sulfonyl benzimidazole derivatives
|
US20060111416A1
(en)
*
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
CA2601508C
(en)
|
2005-03-17 |
2012-01-03 |
Pfizer, Inc. |
Cyclopropanecarboxamide derivatives
|
US20110152326A1
(en)
*
|
2005-03-28 |
2011-06-23 |
Takeshi Hanazawa |
Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
|
US7645786B2
(en)
*
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
DE602006012042D1
(de)
*
|
2005-06-15 |
2010-03-18 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
US20070149464A1
(en)
*
|
2005-06-15 |
2007-06-28 |
Pfizer Inc. |
Combination
|
CA2617654A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Pfizer Limited |
Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
|
CA2618103A1
(en)
*
|
2005-08-10 |
2007-02-15 |
Pfizer Limited |
Substituted triazole derivatives as oxytocin antagonists
|
US7678821B2
(en)
|
2005-09-02 |
2010-03-16 |
Theravida, Inc. |
Compositions for the treatment of overactive bladder
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US20090062326A1
(en)
*
|
2006-03-17 |
2009-03-05 |
Spindel Eliot R |
M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
|
JP5457830B2
(ja)
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
KR20090007792A
(ko)
|
2006-05-09 |
2009-01-20 |
화이자 프로덕츠 인크. |
시클로알킬아미노산 유도체 및 이들의 제약 조성물
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
JP2010500336A
(ja)
*
|
2006-08-09 |
2010-01-07 |
ファイザー・プロダクツ・インク |
炭酸脱水酵素阻害剤として有用な複素環
|
WO2008031221A1
(en)
*
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
CA2657550C
(en)
*
|
2006-09-21 |
2011-11-01 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
MX2009008284A
(es)
|
2007-02-02 |
2009-08-12 |
Pfizer Prod Inc |
Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides.
|
CA2687944A1
(en)
*
|
2007-05-24 |
2008-11-27 |
Pfizer Limited |
Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
|
CN101084891A
(zh)
*
|
2007-06-29 |
2007-12-12 |
北京本草天源药物研究院 |
一种用于口服的达非那新或其药用盐的药物制剂
|
US20090005431A1
(en)
*
|
2007-06-30 |
2009-01-01 |
Auspex Pharmaceuticals, Inc. |
Substituted pyrrolidines
|
US8323695B2
(en)
|
2007-08-13 |
2012-12-04 |
Mcneil-Ppc, Inc. |
Method for stabilizing phenylephrine
|
CZ200845A3
(cs)
*
|
2008-01-28 |
2009-09-02 |
Zentiva, A. S. |
Zpusob prípravy Darifenacinu
|
WO2009105887A1
(en)
*
|
2008-02-26 |
2009-09-03 |
Ernest Puil |
Cyclic amino acids for the treatment of pain
|
WO2009140078A1
(en)
*
|
2008-05-16 |
2009-11-19 |
The Procter & Gamble Company |
Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
|
EP2286810A4
(de)
*
|
2008-05-16 |
2011-07-20 |
Axis Inc |
Pharmazeutische zusammensetzung zur behandlung von fibromyalgie
|
US8435564B2
(en)
*
|
2008-05-30 |
2013-05-07 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising brivaracetam
|
ES2378513T3
(es)
*
|
2008-08-06 |
2012-04-13 |
Pfizer Inc. |
Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
US8252790B2
(en)
|
2008-11-21 |
2012-08-28 |
Raqualia Pharma Inc. |
Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity
|
PL2385938T3
(pl)
|
2009-01-12 |
2015-07-31 |
Pfizer Ltd |
Pochodne sulfonamidu
|
US8828937B2
(en)
|
2009-03-12 |
2014-09-09 |
Haase Investments Ug |
Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
EP2236516A1
(de)
|
2009-03-31 |
2010-10-06 |
Charité-Universitätsmedizin Berlin (Charité) |
Polypeptide und deren Verwendung zur Behandlung von traumatischer oder degenerativer Nervenläsion
|
SG175738A1
(en)
|
2009-05-29 |
2011-12-29 |
Pfizer Ltd |
Novel glucocorticoid receptor agonists
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8617763B2
(en)
*
|
2009-08-12 |
2013-12-31 |
Bloom Energy Corporation |
Internal reforming anode for solid oxide fuel cells
|
BR112012013801A2
(pt)
|
2009-12-11 |
2019-09-24 |
Du Pont |
composto,método para inibir a atividade de hidrolase de amida de ácido graxo em um indivíduo,composição farmacêutica e método para tratar um individuo com dor
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
MX2012007402A
(es)
|
2009-12-23 |
2012-08-23 |
Takeda Pharmaceutical |
Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
|
GB2479213B
(en)
|
2010-04-01 |
2013-07-10 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
JP2013525476A
(ja)
|
2010-05-04 |
2013-06-20 |
ファイザー・インク |
Alk阻害剤としての複素環式誘導体
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
WO2011161504A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Micro Labs Limited |
Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
|
CA2804593C
(en)
|
2010-07-09 |
2015-11-24 |
Pfizer Limited |
Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
|
ES2532356T3
(es)
|
2010-07-09 |
2015-03-26 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
US9096558B2
(en)
|
2010-07-09 |
2015-08-04 |
Pfizer Limited |
N-sulfonylbenzamide compounds
|
JP2013536165A
(ja)
|
2010-07-12 |
2013-09-19 |
ファイザー・リミテッド |
痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
|
JP2013532186A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
化合物
|
CA2801032A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
|
WO2012007868A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
ES2526981T3
(es)
|
2010-07-12 |
2015-01-19 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
MX343274B
(es)
|
2010-11-15 |
2016-10-31 |
Viiv Healthcare Uk Ltd |
Inhibidores de la replicacion del vih.
|
EP2457900A1
(de)
|
2010-11-25 |
2012-05-30 |
Almirall, S.A. |
Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
|
EP2463289A1
(de)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]Pyridazin-Derivate als AS JAK-Hemmer
|
CN102048706B
(zh)
*
|
2011-01-12 |
2012-02-22 |
山东创新药物研发有限公司 |
一种氢溴酸达非那新缓释片及制备方法
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
EP2489663A1
(de)
|
2011-02-16 |
2012-08-22 |
Almirall, S.A. |
Verbindungen als Syk-Kinasehemmer
|
JP5931933B2
(ja)
|
2011-02-25 |
2016-06-08 |
武田薬品工業株式会社 |
N−置換オキサジノプテリジンおよびオキサジノプテリジノン
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
JP5595616B2
(ja)
|
2011-04-05 |
2014-09-24 |
ファイザー・リミテッド |
トロポミオシン関連キナーゼ阻害薬としてのピロロ[2,3−d]ピリミジン誘導体
|
EP2518070A1
(de)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Pyrrolotriazinonderivate als PI3K-Inhibitoren
|
EP2518071A1
(de)
|
2011-04-29 |
2012-10-31 |
Almirall, S.A. |
Imidazopyridinderivate als PI3K-Inhibitoren
|
CN103813792B
(zh)
|
2011-05-10 |
2015-11-25 |
塞拉维达公司 |
用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合
|
WO2012154775A1
(en)
|
2011-05-10 |
2012-11-15 |
Theravida, Inc. |
Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
|
KR102459766B1
(ko)
|
2011-05-18 |
2022-10-26 |
라퀄리아 파마 인코포레이티드 |
4-{[4-({[4-(2,2,2-트리플루오로에톡시)-1,2-벤즈이속사졸-3-일]옥시}메틸)피페리딘-1-일]메틸}-테트라히드로-2h-피란-4-카르복실산의 다형
|
EP2526945A1
(de)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
Neue CRTH2-Antagonisten
|
EP2527344A1
(de)
|
2011-05-25 |
2012-11-28 |
Almirall, S.A. |
Als Medikamente zur Behandlung von myeloproliferativen Krankheiten, Transplantatabstossung, immunbedingten und entzündlichen Erkrankungen geeignete Pyridin-2(1H-)-on-Derivate
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
EP2548876A1
(de)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
Neue CRTH2-Antagonisten
|
EP2548863A1
(de)
|
2011-07-18 |
2013-01-23 |
Almirall, S.A. |
Neue CRTH2-Antagonisten
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2554544A1
(de)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1H-)-on-Derivate als JAK-Inhibitoren
|
BR112014002141A2
(pt)
|
2011-08-02 |
2017-02-21 |
Pfizer |
crizotinib para uso no tratamento de câncer
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
CN104271128A
(zh)
|
2011-10-19 |
2015-01-07 |
佐蒂斯有限责任公司 |
氨基乙腈衍生物针对体内寄生虫的用途
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
CN103906746B
(zh)
|
2011-10-26 |
2015-12-09 |
辉瑞有限公司 |
用作钠通道调节剂的(4-苯基咪唑-2-基)乙胺衍生物
|
WO2013061297A1
(en)
|
2011-10-28 |
2013-05-02 |
Pfizer Limited |
Pyridazine Derivatives Useful in Therapy
|
CA2857603C
(en)
|
2011-12-15 |
2016-08-02 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
CN102579379B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种药物缓释制剂及其制备方法
|
CN102600096B
(zh)
*
|
2011-12-29 |
2016-08-10 |
北京科信必成医药科技发展有限公司 |
一种达非那新缓释制剂及其制备方法
|
CA2860553C
(en)
|
2012-01-04 |
2016-08-23 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
ES2548228T3
(es)
|
2012-02-03 |
2015-10-15 |
Pfizer Inc |
Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
|
EP2822953B9
(de)
|
2012-03-06 |
2017-06-21 |
Pfizer Inc |
Makrocyclische derivate zur behandlung von proliferativen erkrankungen
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
US9353062B2
(en)
|
2012-04-04 |
2016-05-31 |
Hangzhouderenyucheng Biotechnology Ltd |
Substituted quinolines as bruton's tyrosine kinases inhibitors
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
EP2909212B1
(de)
|
2012-09-07 |
2017-02-22 |
Takeda Pharmaceutical Company Limited |
Substituierte 1,4-dihydropyrazolo[4,3-b]indole
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
JP2015531393A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
トロポミオシン関連キナーゼ阻害剤
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
US9163021B2
(en)
|
2012-10-04 |
2015-10-20 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
WO2014060431A1
(en)
|
2012-10-16 |
2014-04-24 |
Almirall, S.A. |
Pyrrolotriazinone derivatives as pi3k inhibitors
|
SG11201502884TA
(en)
|
2012-11-08 |
2015-05-28 |
Pfizer |
Heteroaromatic compounds as dopamine d1 ligands
|
BR112015010620A2
(pt)
|
2012-11-08 |
2017-07-11 |
Pfizer |
compostos heteroaromáticos e seus usos como ligantes de dopamina d1
|
BR112015011392A2
(pt)
|
2012-11-21 |
2017-07-11 |
Raqualia Pharma Inc |
formas polimórficas de ácidos, processo de preparação, composição farmacêutica e uso das mesmas
|
MD20150049A2
(ro)
|
2012-12-03 |
2015-11-30 |
Pfizer Inc. |
Modulatori selectivi noi de receptor androgenic
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
AR094797A1
(es)
|
2013-02-15 |
2015-08-26 |
Almirall Sa |
Derivados de pirrolotriazina como inhibidores de pi3k
|
CN107759594A
(zh)
|
2013-02-21 |
2018-03-06 |
辉瑞大药厂 |
选择性cdk4/6抑制剂的固态形式
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
WO2014140159A1
(en)
*
|
2013-03-13 |
2014-09-18 |
Ratiopharm Gmbh |
Dosage form comprising crizotinib
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
WO2014186742A2
(en)
|
2013-05-17 |
2014-11-20 |
Acupac Packaging, Inc. |
Anhydrous hydrogel composition
|
NZ713762A
(en)
|
2013-06-27 |
2018-03-23 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
CA2934010A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2015092614A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Inc. |
Activating notch alterations in breast cancer
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
UY35945A
(es)
|
2014-01-09 |
2015-08-31 |
Takeda Pharmaceutical |
Derivados de azaindol
|
EP3131891A1
(de)
|
2014-04-15 |
2017-02-22 |
Pfizer Inc. |
Tropomysin-verwandte kinaseinhibitoren mit einer 1h-pyrazol- sowie pyrimidineinheit
|
PE20170008A1
(es)
|
2014-04-25 |
2017-03-17 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
MA39914A
(fr)
|
2014-04-25 |
2017-03-01 |
Pfizer |
Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
|
US9745317B2
(en)
|
2014-04-28 |
2017-08-29 |
Pfizer Inc. |
Heterocyclic compounds and their use as dopamine D1 ligands
|
EP3137454A1
(de)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
|
EP3140298A1
(de)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-assoziierte kinaseinhibitoren
|
WO2015173683A1
(en)
|
2014-05-14 |
2015-11-19 |
Pfizer Inc. |
Pyrazolopyridines and pyrazolopyrimidines
|
KR101817889B1
(ko)
|
2014-05-15 |
2018-01-11 |
화이자 인코포레이티드 |
6-[(4r)-4-메틸-1,2-다이옥사이도-1,2,6-티아다이아지난-2-일]이소퀴놀린-1-카보니트릴의 결정질 형태
|
ES2747989T3
(es)
|
2014-05-20 |
2020-03-12 |
Raqualia Pharma Inc |
Sal de derivado de benzisoxazol
|
US20170275275A1
(en)
|
2014-05-30 |
2017-09-28 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
CA2950390C
(en)
|
2014-05-30 |
2020-09-22 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
EP3157915B1
(de)
|
2014-06-17 |
2019-02-27 |
Pfizer Inc |
Substituierte dihydroisochinolinonverbindungen
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
US10017529B2
(en)
|
2014-09-16 |
2018-07-10 |
BioPharma Works LLC |
Metformin derivatives
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
US9765000B2
(en)
|
2015-01-22 |
2017-09-19 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids, compositions and kits thereof
|
MX2017010844A
(es)
|
2015-02-24 |
2017-12-07 |
Pfizer |
Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
|
EP3268046A4
(de)
|
2015-03-13 |
2018-11-21 |
Endocyte, Inc. |
Konjugate zur behandlung einer erkrankung
|
US10214509B2
(en)
|
2015-04-21 |
2019-02-26 |
Almirall, S.A. |
Amino-substituted heterocyclic derivatives as sodium channel inhibitors
|
PT3302565T
(pt)
|
2015-06-04 |
2020-01-14 |
Pfizer |
Formas de dosagem sólida de palbociclib
|
EA035823B1
(ru)
|
2015-07-31 |
2020-08-17 |
Пфайзер Инк. |
1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
|
WO2017060488A1
(en)
|
2015-10-09 |
2017-04-13 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017064068A1
(en)
|
2015-10-14 |
2017-04-20 |
Almirall, S.A. |
New trpa1 antagonists
|
WO2017098367A1
(en)
|
2015-12-10 |
2017-06-15 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
AR107132A1
(es)
|
2015-12-24 |
2018-03-21 |
Takeda Pharmaceuticals Co |
Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
|
JP2019501222A
(ja)
|
2016-01-07 |
2019-01-17 |
シーエス ファーマテック リミテッド |
Egfrチロシンキナーゼの臨床的に重要な変異体の選択的阻害薬
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
CN108884093B
(zh)
|
2016-01-15 |
2021-07-09 |
辉瑞公司 |
一种多巴胺d3配体化合物
|
CA3011683C
(en)
|
2016-01-20 |
2023-09-26 |
Theravida, Inc. |
Methods and compositions for treating hyperhidrosis
|
WO2017156341A1
(en)
|
2016-03-09 |
2017-09-14 |
Beijing Percans Oncology Co. Ltd. |
Tumor cell suspension cultures and related methods
|
ES2886080T3
(es)
|
2016-03-31 |
2021-12-16 |
Takeda Pharmaceuticals Co |
Complejos de isoquinolinil triazolona
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
EP3496724B8
(de)
|
2016-08-12 |
2021-11-17 |
Madera Therapeutics, LLC |
Proteinkinaseregulatoren
|
RS61934B1
(sr)
|
2016-08-15 |
2021-07-30 |
Pfizer |
Inhibitori piridopirimdinona cdk2/ 4/6
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
KR20190104405A
(ko)
|
2017-01-20 |
2019-09-09 |
화이자 인코포레이티드 |
Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
|
JP2020506903A
(ja)
|
2017-01-23 |
2020-03-05 |
ファイザー・インク |
Magl阻害薬としての複素環式スピロ化合物
|
EP3573995A1
(de)
|
2017-01-24 |
2019-12-04 |
Pfizer Inc. |
Calicheamicin-derivate und antikörper-wirkstoff-konjugate davon
|
DK3600312T3
(da)
|
2017-03-26 |
2023-07-31 |
Takeda Pharmaceuticals Co |
Piperidinyl- og piperazinylsubstituerede heteroaromatiske carboxamider som modulatorer af gpr6
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
EP3642198B1
(de)
|
2017-06-22 |
2022-03-16 |
Curadev Pharma Limited |
Kleinmolekülige modulatoren von menschlichem sting
|
AU2018323053A1
(en)
|
2017-08-30 |
2020-03-19 |
Beijing Xuanyi Pharmasciences Co., Ltd |
Cyclic di-nucleotides as stimulator of interferon genes modulators
|
EP3681879A1
(de)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals, Inc. |
Allosterische octahydrocyclopenta[c]pyrrolinhibitoren von shp2
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
US11529344B2
(en)
|
2017-11-14 |
2022-12-20 |
Pfizer Inc. |
EZH2 inhibitor combination therapies
|
CN111788171A
(zh)
|
2018-01-29 |
2020-10-16 |
菲拓普兰特研究公司 |
使用液:液色谱法纯化大麻素的方法
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
US20200405809A1
(en)
|
2018-02-27 |
2020-12-31 |
Pfizer Inc. |
Combination of a cyclin dependent kinase inhibitor and a bet- bromodomain inhibitor
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
CR20200503A
(es)
|
2018-04-26 |
2020-12-17 |
Pfizer |
Inhibidores de cinasa dependientes de ciclina
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
JP2021531287A
(ja)
|
2018-07-19 |
2021-11-18 |
ファイザー・インク |
Magl阻害剤としての複素環式スピロ化合物
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
AU2020211789A1
(en)
|
2019-01-23 |
2021-07-22 |
Pfizer Inc. |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
KR20210121186A
(ko)
|
2019-01-31 |
2021-10-07 |
화이자 인코포레이티드 |
Cdk2에 대한 억제 활성을 갖는 3-카본일아미노-5-사이클로펜틸-1h-피라졸 화합물
|
WO2020157709A1
(en)
|
2019-02-01 |
2020-08-06 |
Pfizer Inc. |
Combination of a cdk inhibitor and a pim inhibitor
|
CN113795251A
(zh)
|
2019-02-27 |
2021-12-14 |
马德拉治疗公司 |
酪蛋白水解蛋白酶p功能作为药物对imipridone样试剂响应的生物标志物的用途
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
GB201905375D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
GB201905371D0
(en)
|
2019-04-16 |
2019-05-29 |
Mission Therapeutics Ltd |
Novel compounds
|
MA55804A
(fr)
|
2019-04-29 |
2022-04-06 |
Solent Therapeutics Llc |
Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
EP4003961A2
(de)
|
2019-07-25 |
2022-06-01 |
Curadev Pharma Pvt. Ltd. |
Inhibitoren kleiner moleküle von acetyl-coenzym a synthetase-kurzketten 2 (acss2)
|
GB201912674D0
(en)
|
2019-09-04 |
2019-10-16 |
Mission Therapeutics Ltd |
Novel compounds
|
JP2022548602A
(ja)
|
2019-09-16 |
2022-11-21 |
武田薬品工業株式会社 |
アゾール縮合ピリダジン-3(2h)-オン誘導体
|
AU2021219370A1
(en)
|
2020-02-12 |
2022-08-25 |
Curadev Pharma Pvt. Ltd. |
Small molecule STING antagonists
|
TW202146017A
(zh)
|
2020-03-05 |
2021-12-16 |
美商輝瑞股份有限公司 |
間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
CN115461340A
(zh)
|
2020-04-08 |
2022-12-09 |
特殊治疗有限公司 |
具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
CN115698004A
(zh)
|
2020-05-01 |
2023-02-03 |
辉瑞公司 |
作为hpk1抑制剂的氮杂内酰胺化合物
|
EP4146625A1
(de)
|
2020-05-04 |
2023-03-15 |
Takeda Pharmaceutical Company Limited |
Luminal wirkende n-(piperidin-4-yl)benzamidderivate
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
US20230219939A1
(en)
|
2020-05-28 |
2023-07-13 |
Mission Therapeutics Limited |
N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
|
US20230303547A1
(en)
|
2020-06-04 |
2023-09-28 |
Mission Therapeutics Limited |
N-cyanopyrrolidines with activity as usp30 inhibitors
|
CA3186148A1
(en)
|
2020-06-08 |
2021-12-16 |
Mission Therapeutics Limited |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
US20230321042A1
(en)
|
2020-07-20 |
2023-10-12 |
Pfizer Inc. |
Combination therapy
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
BR112023002295A2
(pt)
|
2020-08-13 |
2023-03-14 |
Pfizer |
Terapia de combinação
|
KR20230069983A
(ko)
|
2020-09-15 |
2023-05-19 |
화이자 인코포레이티드 |
Cdk4 억제제의 고체 형태
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
GB202016800D0
(en)
|
2020-10-22 |
2020-12-09 |
Mission Therapeutics Ltd |
Novel compounds
|
IL303932A
(en)
|
2020-12-22 |
2023-08-01 |
Pfizer |
Solid forms of EIF4E inhibitor
|
EP4267563A1
(de)
|
2020-12-24 |
2023-11-01 |
Pfizer Inc. |
Feste formen eines cdk2-inhibitors
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
WO2022200982A1
(en)
|
2021-03-24 |
2022-09-29 |
Pfizer Inc. |
Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
|
JP2024512979A
(ja)
|
2021-03-31 |
2024-03-21 |
セブンレス セラピューティクス リミテッド |
疼痛の新しい処置
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
EP4320121A2
(de)
|
2021-04-07 |
2024-02-14 |
LifeArc |
2,4-diaminopyrimidinderivate als ulk1/2-inhibitoren und deren verwendung
|
WO2022229846A1
(en)
|
2021-04-29 |
2022-11-03 |
Pfizer Inc. |
Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
|
WO2022269531A1
(en)
|
2021-06-26 |
2022-12-29 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
WO2023002362A1
(en)
|
2021-07-22 |
2023-01-26 |
Pfizer Inc. |
Treatment of hematological malignancy
|
IL310679A
(en)
|
2021-08-11 |
2024-04-01 |
Curadev Pharma Pvt Ltd |
Urea history of small molecules as STING antagonists
|
KR20240046742A
(ko)
|
2021-08-11 |
2024-04-09 |
큐라데브 파마 프라이버트 리미티드 |
소분자 sting 길항제
|
WO2023084459A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating sars-cov-2
|
WO2023099561A1
(en)
|
2021-12-01 |
2023-06-08 |
Mission Therapeutics Limited |
Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023100134A1
(en)
|
2021-12-02 |
2023-06-08 |
Pfizer Inc. |
Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
WO2023194964A1
(en)
|
2022-04-07 |
2023-10-12 |
Takeda Pharmaceutical Company Limited |
Fused pyridazine derivatives as nlrp3 inhibitors
|
WO2024013567A1
(en)
|
2022-07-15 |
2024-01-18 |
Jazz Pharmaceuticals Ireland Limited |
Biaryl ether urea compounds as faah inhibitors
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024033513A1
(en)
|
2022-08-11 |
2024-02-15 |
Diaccurate |
Compounds for treating cancer
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
WO2024105363A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
|